secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001724521-24-000090
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q1 revenue jumps to $145M, net loss $4M; pipeline advances with ASCO presentations and Phase 3 enrollments
--------------------------------------------------------------------------------

- Revenue $145M vs $25M YoY, including $135M license revenue from Gilead collaboration amendments.
- Net loss $4M vs $80M YoY; cash $1.1B at quarter end; year-end 2024 cash expected $870-920M.
- R&D expenses $109M (up from $81M); $20M impairment charge for facility sublease.
- Two oral presentations at ASCO 2024: EDGE-Gastric (domvanalimab) and ARC-9 (etrumadenant) in GI cancers.
- Phase 3 STAR-221 enrollment expected mid-2024; STAR-121 H2 2024; first Phase 3 for casdatifan in ccRCC planned H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000090/0001724521-24-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000090/rcus-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001724521-24-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer